An investigation of the ability of orally primed and tolerised T cells to help B cells upon mucosal challenge.

Immunology

Division of Immunology, Infection and Inflammation, Western Infirmary, University of Glasgow, Glasgow G11 6NT, Scotland, UK.

Published: August 2004

The oral delivery of soluble antigens induces unresponsiveness to systemic challenge that can be demonstrated as a reduced ability of tolerised T cells to support B-cell expansion and antibody production. However, it remains controversial whether previously induced oral tolerance results in suppression or priming, or has no effect on B-cell responses upon oral challenge. Using a double adoptive transfer system, we primed or tolerised T cells (independently of B cells) with a high dose of fed antigen, and examined the ability of these primed or tolerised T cells to support B-cell clonal expansion in response to orally delivered conjugated antigen. We demonstrated directly in vivo that, in contrast to orally primed T cells, transgenic T cells tolerised by feeding a high dose of antigen are incapable of providing cognate help to support B-cell clonal expansion and antibody production in response to oral challenge. This defect appears to be a result of a reduced ability of orally tolerised transgenic T cells to clonally expand and migrate to B-cell follicles after oral challenge.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1782527PMC
http://dx.doi.org/10.1111/j.1365-2567.2004.01913.xDOI Listing

Publication Analysis

Top Keywords

tolerised cells
16
primed tolerised
12
support b-cell
12
oral challenge
12
cells
9
ability orally
8
orally primed
8
reduced ability
8
cells support
8
expansion antibody
8

Similar Publications

Background: The complex aetiology of type 1 diabetes (T1D), characterised by a detrimental cross-talk between the immune system and insulin-producing beta cells, has hindered the development of effective disease-modifying therapies. The discovery that the pharmacological activation of LRH-1/NR5A2 can reverse hyperglycaemia in mouse models of T1D by attenuating the autoimmune attack coupled to beta cell survival/regeneration prompted us to investigate whether immune tolerisation could be translated to individuals with T1D by LRH-1/NR5A2 activation and improve islet survival.

Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from individuals with and without T1D and derived into various immune cells, including macrophages and dendritic cells.

View Article and Find Full Text PDF

Aims/hypothesis: We hypothesised that islet beta cell antigen presentation in the gut along with a tolerising cytokine would lead to antigen-specific tolerance in type 1 diabetes. We evaluated this in a parallel open-label Phase 1b study using oral AG019, food-grade Lactococcus lactis bacteria genetically modified to express human proinsulin and human IL-10, as a monotherapy and in a parallel, randomised, double-blind Phase 2a study using AG019 in combination with teplizumab.

Methods: Adults (18-42 years) and adolescents (12-17 years) with type 1 diabetes diagnosed within 150 days were enrolled, with documented evidence of at least one autoantibody and a stimulated peak C-peptide level >0.

View Article and Find Full Text PDF

Associated with the development of hospital-acquired infections, major traumatic injury results in an immediate and persistent state of systemic immunosuppression, yet the underlying mechanisms are poorly understood. Detected in the circulation in the minutes, days and weeks following injury, damage associated molecular patterns (DAMPs) are a heterogeneous collection of proteins, lipids and DNA renowned for initiating the systemic inflammatory response syndrome. Suggesting additional immunomodulatory roles in the post-trauma immune response, data are emerging implicating DAMPs as potential mediators of post-trauma immune suppression.

View Article and Find Full Text PDF

Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis.

Ann Rheum Dis

August 2022

Immune Regulation and Tolerance Research Group, Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas (ICBM), Universidad de Chile Facultad de Medicina, Santiago, Chile

Objective: Rheumatoid arthritis (RA) immunopathogenesis revolves around the presentation of poorly characterised self-peptides by human leucocyte antigen (HLA)-class II molecules on the surface of antigen-presenting cells to autoreactive CD4 +T cells. Here, we analysed the HLA-DR-associated peptidome of synovial tissue (ST) and of dendritic cells (DCs) pulsed with synovial fluid (SF) or ST, to identify potential T-cell epitopes for RA.

Methods: HLA-DR/peptide complexes were isolated from RA ST samples (n=3) and monocyte-derived DCs, generated from healthy donors carrying RA-associated shared epitope positive HLA-DR molecules and pulsed with RA SF (n=7) or ST (n=2).

View Article and Find Full Text PDF

Background: Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O methylguanine DNA methyltransferase (MGMT) that renders the tumors resistant to temozolomide (TMZ). We hypothesized that pretreatment with bortezomib (BTZ) 48 hours prior to TMZ to deplete MGMT levels would be safe and tolerated by patients with recurrent GBM harboring unmethylated MGMT promoter.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!